The Smart Ring Revolution Just Hit a Tipping Point: What the Latest Industry Shake-Ups Mean for Your Wallet and Your Health

This past week, the smart ring industry experienced the most consequential seven days in its short history—and the two headline stories could not be more contradictory.

On September 21, Oura formally launched its US IPO roadshow, targeting a fully diluted valuation of $15.62 billion and seeking up to $2.2 billion in proceeds. Just weeks earlier, the company was hit with a proposed class-action lawsuit in California’s Northern District Court, alleging that its sleep tracking accuracy claims misled consumers. The lawsuit’s most damaging phrase, widely circulated on social media, was devastating in its simplicity: “Sleep happens in the brain, not in the finger.”

Here is the uncomfortable truth every smart ring consumer needs to confront: The most popular sleep tracker in the world is being accused of producing data that, when it comes to distinguishing sleep stages, is barely better than flipping a coin. And it’s about to become a publicly traded company valued at nearly $16 billion.

Understanding what’s happening right now—and what the science actually says—could save you hundreds of dollars and a lot of unnecessary anxiety.

1. The Lawsuit’s Core Argument: Why Your Ring Can’t Read Your Brain

Let’s start with the science, because the lawsuit’s argument is rooted in a fundamental technical limitation that no amount of software updates can overcome.

When a hospital evaluates your sleep, the gold standard is polysomnography (PSG) —electrodes attached to your scalp, face, and body that directly record brain waves (EEG), eye movements (EOG), and muscle activity (EMG). This is how clinicians determine whether you are in light sleep, deep sleep, or REM sleep.

Your smart ring, by contrast, can only collect heart rate, heart rate variability (HRV), movement, breathing patterns, and skin temperature. It cannot read brain waves. Every single “sleep stage” your ring reports is an inference—an algorithmic guess based on peripheral signals.

The lawsuit cites a 2025 study published in Scientific Reports, conducted by researchers at Charité University Hospital in Berlin. Forty-five patients with sleep disorders underwent simultaneous PSG monitoring and wore a third-generation Oura ring. The results were stark:

• Distinguishing “asleep” from “awake”: 85.03% accuracy—usable, with an average overestimation of total sleep time by about 11.7 minutes.

• Distinguishing sleep stages (light vs. deep vs. REM): Overall accuracy plummeted to 53.18%. REM sleep was overestimated by an average of 31.6 minutes.

Fifty-three percent. For context, a coin flip is 50%.

To be fair, this study involved clinical patients and only one night of data. Oura has publicly defended its technology, and individual results vary. But the core finding—that stage-level sleep tracking from a finger is inherently limited—is not scientifically controversial. It is a physical constraint.

2. Oura’s Business Model Makes the Accuracy Question Even More Urgent

Here is where the lawsuit’s timing becomes especially significant. Oura isn’t just selling hardware. It’s selling a subscription.

The company’s IPO filing reveals that membership revenue more than doubled year-over-year to $240.5 million, carrying an 89% gross margin—compared to just 24% on hardware. More than 94% of ring activations convert to paid membership after the initial trial. In the U.S., that membership costs $5.99 per month or $69.99 per year.

The Oura Ring 5 itself starts at $399. Over three years, the total cost of ownership easily exceeds $600.

Oura CEO Tom Hale has defended the subscription model, arguing that the recurring fee “funds the steady stream of updates that keep the product valuable long after the ring is sold”. That’s a reasonable argument in principle.

But when the core value proposition—accurate, actionable sleep insights—is being challenged in court, the question becomes unavoidable: What exactly am I paying $70 per year for? Continuous updates to an algorithm that, at the stage level, performs roughly as well as chance?

3. The “Pseudoprecision” Problem: Why Bad Data Can Be Worse Than No Data

There’s a deeper issue here that extends beyond Oura specifically. It’s what Chinese clinicians have begun calling “pseudoprecision” .

Dr. Lin Yi, an endocrinologist at Shanghai General Hospital, explains the problem this way: a smart ring might report that your weight dropped after starting a keto diet. The number looks precise. But what if you lost muscle and water, not fat? The data provided positive feedback that reinforced a potentially unhealthy behavior.

The same logic applies to sleep. Your ring tells you your deep sleep was “insufficient.” You feel anxious. You try to sleep more. You can’t. Your anxiety worsens. Your sleep deteriorates further.

Dr. Liu Fei, a psychiatrist at Tongji Hospital in Shanghai, has seen this pattern repeatedly in his clinic. Patients become obsessed with checking their heart rate and blood oxygen every few minutes, creating a feedback loop of “the more I check, the more anxious I get; the more anxious I get, the more I check”.

Smart rings, because they are worn continuously and unobtrusively, make this cycle even more insidious. The device that was supposed to help you sleep better becomes the source of the stress keeping you awake.

China’s National Health Commission has already issued a clear position: consumer wearable device monitoring cannot be used as a basis for disease diagnosis or treatment, and cannot replace medical examinations.

4. What This Means for You: A Practical Buying Framework

So where does this leave consumers? Here’s a straightforward framework:

If you already own a smart ring:

Stop treating single-night scores as gospel. Look at weekly and monthly trends instead. A single “58” after a late dinner or a stressful day is not a medical event. If you find yourself checking the app multiple times per day or feeling genuine distress about your sleep score, that’s a sign to take a break from the data—not to buy a more expensive ring.

If you’re considering buying a smart ring:

Ask yourself one question: What problem am I trying to solve?

If the answer is “I want a general sense of my sleep patterns and recovery trends,” a smart ring can be useful—as long as you understand its limitations. Oura remains the most polished option, and its activity and readiness metrics are generally well-regarded.

If the answer is “I want to diagnose or manage a sleep disorder,” a smart ring is the wrong tool. You need a clinical sleep study, not a consumer wearable.

If the answer is “I want accurate sleep stage data without a subscription,” you should know that no consumer ring currently delivers clinically validated stage-level accuracy. The technology simply isn’t there yet.

If you’re an investor watching the IPO:

The bull case for Oura is its subscription economics—89% gross margins on recurring revenue are exceptional by any standard. The bear case is the accuracy lawsuit, which, if successful, could force changes to marketing claims and potentially open the door to broader regulatory scrutiny. The IPO’s pricing on September 29 will be the market’s first real verdict on which narrative it believes.

The Bottom Line

Oura’s IPO represents a genuine milestone for the smart ring category. It proves that consumers are willing to pay for discreet, continuous health monitoring, and that a subscription model can work for hardware.

But the lawsuit represents something equally important: a necessary correction to the hype. Smart rings are remarkable engineering achievements. They are also fundamentally limited by the physics of what a finger-based sensor can detect.

The most valuable thing you can do as a consumer is to use the data as a prompt for curiosity, not a source of certainty. If your ring says your sleep was poor, ask yourself how you actually feel. If the answer is “fine,” trust your body over the algorithm.

Technology should serve your health. It should never dictate your peace of mind.